Drug intelligence / Profile preview

SCUT1-2

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

SCUT1-2 is a bifunctional antibacterial agent with demonstrated oral bioavailability in mice (F=56.8%). It exhibits potent activity against Clostridioides difficile, effectively killing its vegetative cells with a low minimum inhibitory concentration (MIC). The compound is being investigated as an anti-infective, particularly for its potential to treat bacterial infections such as C. difficile[1][3]. Its precise mechanism of action has not been fully elucidated in the public domain, but it is characterized as an antibacterial small molecule.

Beyond the preview

Go deeper on SCUT1-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCUT1-2.

Explore the full profile